Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 71Carcinoma, Non-Small-Cell Lung 69Multiple Myeloma 55Prostatic Neoplasms 54Colorectal Neoplasms 42Leukemia, Myeloid, Acute 39Neoplasms 38Melanoma 34Lymphoma 33Ovarian Neoplasms 30Lymphoma, Non-Hodgkin 29Lung Neoplasms 28Squamous Cell Carcinoma of Head and Neck 27Sarcoma 27Neoplasm Metastasis 25Carcinoma, Hepatocellular 24Pancreatic Neoplasms 23Endometrial Neoplasms 23Glioma 22Carcinoma, Renal Cell 22Lymphoma, Large B-Cell, Diffuse 21Hodgkin Disease 21Recurrence 20Leukemia, Lymphocytic, Chronic, B-Cell 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Myelodysplastic Syndromes 18Esophageal Neoplasms 17Hematologic Neoplasms 16

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Respiratory Tract Infections × 30 days × Clear all
NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡